These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at their medium- to long-term outlook.” ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings. Coca-Cola on ...

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

CEO Vas Narasimhan said the company has more than 25 potential blockbusters in its pipeline. Psoriasis drug Cosentyx and heart failure drug Entresto are leading the charge among the company’s ...

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in ...

“We've taken, I think, appropriate actions with inventory levels and in terms of managing our supply chain to enable us to ...